COVID-19 updates: Pfizer vaccine highly effective in children 5-11

About 64.3 million Americans ages 12 and older are completely unvaccinated.

More than 731,000 Americans have died from COVID-19 while over 4.9 million people have died from the disease worldwide, according to real-time data compiled by the Center for Systems Science and Engineering at Johns Hopkins University.

Just 66.9% of Americans ages 12 and up are fully vaccinated against COVID-19, according to data from the Centers for Disease Control and Prevention.


Your guide to booster eligibility 

The Centers for Disease Control and Prevention have now signed off on boosters for all three COVID-19 vaccines authorized in the U.S., after Thursday's recommendation for the Moderna and Johnson & Johnson shots.

Unsure if you're eligible to receive any of them? Check out ABC News' handy guide.


Delta doesn't cause more severe illness than prior variants: CDC 

A new report from the Centers for Disease Control and Prevention suggests that although the delta variant is significantly more transmissible than prior variants, it is not more likely to lead to hospitalization.

Instead, the dramatic uptick in hospitalizations seen during the summer's delta surge was fueled by the highly transmissible variant spreading easily among mostly unvaccinated people, the CDC said.

The report, which analyzed COVID-19 hospitalization data from 14 states, also found that the proportion of people aged 18 to 49 hospitalized with delta increased "significantly" in July and August to 35.8% of all hospitalizations compared to 24.7% from January to June of this year. This was likely due to lower vaccination rates among younger people, the CDC said.

-ABC News' Sony Salzman


Pfizer vaccine highly effective in children 5-11

The Pfizer COVID-19 vaccine is nearly 91% effective against symptomatic illness in children ages 5-11, according to new data posted Friday ahead of a major FDA advisory committee meeting on Tuesday.

The vaccine also appeared safe, with none of the children experiencing a rare heart inflammation side effect known as myocarditis. If authorized in children 5-11, the Pfizer vaccine will be given at a smaller, one-third dose.

This efficacy estimate is from the company's clinical trial of 2,268 children in which some children got a placebo, and some children got the Pfizer vaccine. During the trial, 16 children who got the placebo shots developed COVID-19. Only three children who got the real vaccine developed COVID-19.

A small number of the children who were vaccinated and later developed COVID-19 experienced symptoms far fewer and milder than the children who were unvaccinated. For example, none of the vaccinated children developed a fever, while a majority of the unvaccinated children developed a fever along with other symptoms.

None of the children experienced serious adverse events. Many experienced typical symptoms like pain at the injection site, fatigue and headache.

The FDA's advisers will meet Tuesday to vote on whether to authorize the vaccine. From there, the FDA itself and the CDC will need to sign off -- a process that can take several days -- before shots could become available to children nationally.

- ABC News' Sony Salzman



CDC signs off on Moderna, J&J boosters

Hours after the unanimous vote from its independent advisory committee, the Centers for Disease Control and Prevention has signed off on recommending booster shots for the Moderna and Johnson & Johnson COVID-19 vaccines for certain populations.

CDC Director Rochelle Walensky recommended boosters for Pfizer and Moderna recipients with no preference on the brand, leaving that decision up to the individual.

People who are 65 and older, or individuals as young as 18 who have underlying medical conditions or live in high-risk or long-term care settings, are eligible to receive either a Pfizer or Moderna booster at least six months after their second shot, the CDC said.

The one-shot Johnson & Johnson vaccine is eligible to anyone aged 18 and up, at least two months after their initial dose, the CDC said.

-ABC News' Eric Strauss


US sees 50% drop in daily cases

Coronavirus infections are steadily falling across the country, thanks to significant declines in highly populated states such as Florida, Texas, Louisiana and Mississippi.

The number of daily cases in the U.S. has dropped 50% since Sept. 1, with a 43% drop in hospitalizations and a 21% drop in daily deaths.

However, an uptick in cases in Northern states is causing some concern.

In recent weeks, coronavirus infections have been creeping up in several states in the Upper Midwest and the Northeast. Eight states — Alaska, Colorado, Idaho, Michigan, Minnesota, New Hampshire, New Mexico, and Vermont — have seen notable jumps in their case averages.

Experts have been warning for weeks that Northern states could begin to see upticks in the coming weeks as winter approaches, and people start to head indoors.

Alaska currently has the country's highest case rate, followed by Montana, Wyoming, Idaho, West Virginia, and North Dakota, which all with case rates above 400 per 100,000 people.

Daily deaths are slowly falling, but remain persistently high. The nation is still reporting an average of 1,250 new deaths each day, and over the last four days alone, the U.S. reported just under 7,000 confirmed COVID-19 deaths.

The death average is still about 6.5 times higher than in mid-July, when the national average had dropped to a near pandemic low of 192 deaths reported each day.

Nationally, hospitalization numbers have dropped to under 60,000 patients with COVID-19 currently receiving care, down from 104,000 patients in late August. Hospital admissions have also fallen by about 10.4% in the last week.

Approximately 113.5 million Americans remain completely unvaccinated. Just under 65.2 million of those people are over the age of 12. The other 48 million unvaccinated people are children under the age of 12.

— ABC News’ Arielle Mitropolous